On August 4, 2025, Prestige Consumer Healthcare Inc. announced a definitive agreement to acquire Pillar5 Pharma Inc., a leading Canadian sterile ophthalmic manufacturer and current supplier of Clear Eyes, from ANJAC Health & Beauty, a French industrial group specializing in the formulation, manufacturing and filling of cosmetics, medical devices, drugs and food supplements, in a deal valued at $150 million.

This acquisition is part of Prestige’s strategy to expand eye care production capacity and address supply chain challenges, with the transaction expected to close in the third quarter of 2026. The company also reported a decline in first-quarter fiscal 2026 revenue to $249.5 million due to supply constraints in the eye care category, although international segment growth and improved gross margins were noted. The acquisition of Pillar5 is anticipated to secure long-term supply chain capacity and support Prestige’s growth opportunities, despite a revised revenue outlook for fiscal 2026.